Latest News - ResMed
Top Corporates Hub
ResMed
Unpacking Q4 Earnings: ResMed (NYSE:RMD) In The Context Of Other Patient Monitoring Stocks
26.03.2026 14:37
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at patient monitoring stocks, starting with ResMed (NYSE:RMD).
ResMed (RMD) Valuation Check After Recent Share Price Pullback And Growth Expectations
22.03.2026 06:05
ResMed stock performance and recent context ResMed (RMD) has drawn attention after recent trading, with shares last closing at US$225.99. The stock shows a 0.6% decline over the past day and softer returns over the week, month, and past 3 months. See our latest analysis for ResMed. Recent trading reflects fading short term momentum, with a 30 day share price return of a 12.8% decline and a year to date share price return of a 7.7% decline, while 1 year total shareholder return is 3.8%. If...
After Plunging 12.0% in 4 Weeks, Here's Why the Trend Might Reverse for ResMed (RMD)
19.03.2026 13:35
ResMed (RMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
ResMed Inc (NYSE:RMD): A Quality Dividend Stock Built on Strong Fundamentals
19.03.2026 12:01
ResMed (RMD) offers a reliable dividend with a 10+ year growth history, backed by strong earnings power and a robust balance sheet for sustainable passive income.
ResMed (RMD) Upgraded to Buy: Here's What You Should Know
17.03.2026 16:00
ResMed (RMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Resmed Stock the Right Pick for Your Portfolio Now?
17.03.2026 14:54
RMD expands mask and device sales while maintaining strong liquidity, but macro and competitive pressures loom.
After Plunging 8.7% in 4 Weeks, Here's Why the Trend Might Reverse for ResMed (RMD)
17.03.2026 13:35
The heavy selling pressure might have exhausted for ResMed (RMD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Is It Time To Reconsider ResMed (RMD) After The Recent Share Price Pullback
14.03.2026 13:09
If you are wondering whether ResMed's current share price still reflects good value or if most of the upside is already priced in, you are in the right place. ResMed shares last closed at US$230.84, with returns of 3.9% over 1 year, 14.7% over 3 years, 29.9% over 5 years, and more recent moves of an 8.7% decline over 7 days and an 11.1% decline over 30 days that may be changing how the market views its risk and return trade off. Recent coverage of ResMed has focused on the company as a major...
Is ResMed Stock Underperforming the Nasdaq?
12.03.2026 10:48
ResMed has underperformed the Nasdaq over the past year, but analysts are cautiously optimistic about the stock’s prospects.
3 Reasons Not to Sleep on ResMed Stock
10.03.2026 18:50
ResMed is a leader in CPAP machines and other medical devices that help millions breathe better.
3 Healthcare Stocks to Target This Week
09.03.2026 09:12
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have seen decent returns lately as healthcare stocks were up 5.7% over the past six months, almost identical to the S&P 500.
Disney, Toast, ServiceNow And A Health Care Stock On CNBC's 'Final Trades'
04.03.2026 08:42
Joshua Brown of Ritholtz Wealth Management likes Toast, and Sarat Sethi is sticking with Disney; Malcolm Ethridge chooses ServiceNow.
Resmed’s Global Sleep Survey Reveals Sleep is One of the Top Health Priorities, but Quality Rest Remains Out of Reach
03.03.2026 08:00
Insights from 30,000 people across 13 countries show global sleep health awareness is growing, yet an action gap remains 53% of people surveyed rank sleep as the most important behavior for a long, healthy life, ahead of diet and exercise.Over half of respondents get quality sleep on only four nights a week or less.While 66% of people surveyed say they would seek medical help for ongoing sleep issues, just 23% actually do. SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD
ResMed Inc (NYSE:RMD): A Durable Dividend Stock Built on Financial Strength
26.02.2026 10:01
ResMed (RMD) exemplifies a quality dividend stock with a 10+ year growth history, strong profitability, and a rock-solid balance sheet for sustainable passive income.
4 GARP Stocks That Investors Can Scoop Up for Maximum Returns
25.02.2026 13:43
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. RL, EAT, FTI and RMD hold promise.
Anti-snoring Devices Market Competitive Landscape Report 2025: Top Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations and Launches, Sustainability Goals, Revenue Insights
24.02.2026 12:00
The anti-snoring devices market is set to expand from $1.81 billion in 2025 to $3.36 billion by 2033, reflecting an 8.04% CAGR. This growth is driven by rising obesity rates, innovative technologies, and demand for non-invasive treatment options. The popularity of these devices is fueled by the increased awareness of the health risks linked with snoring and the convenience of online and offline accessibility. Key players like Philips, ResMed, and SomnoMed lead the market with advanced snoring so
ResMed Inc. (NYSE:RMD) Emerges as a Prime Quality Investing Candidate
23.02.2026 09:01
ResMed exemplifies quality investing with high profitability, strong growth, and a robust balance sheet, making it a durable long-term holding.
If EPS Growth Is Important To You, ResMed (NYSE:RMD) Presents An Opportunity
16.02.2026 13:00
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Invesco International Growth Fund Q4 2025 Portfolio Update
16.02.2026 11:43
Invesco International Growth Fund underperformed most in industrials, consumer discretionary and communication services, all due to stock selection. Read more here.
ResMed (RMD): Buy, Sell, or Hold Post Q4 Earnings?
16.02.2026 04:03
Over the past six months, ResMed’s shares (currently trading at $252.56) have posted a disappointing 11.7% loss, well below the S&P 500’s 5.9% gain. This might have investors contemplating their next move.